拓扑替康联合阿糖胞苷二线治疗血液恶性肿瘤的临床观察

暂未订购

导出

作者罗云娄世锋陈林陈姝周慷

机构地区重庆医科大学附属二院血液内科

出处《医学临床研究》 CAS 2004年第2期183-184,共2页 Journal of Clinical Research

关键词拓扑替康联合用药阿糖胞苷药物治疗血液恶性肿瘤抗肿瘤药

参考文献6

1Nakashio A, Fujita N,Rokudai S, et al. Prevention of phosphatidylinositol 3'-kinase-Akt survival signaling pathway during topotecan-induced apoptosis[J].Cancer Res, 2000,60(18): 5303-5309.
2Beran M, Kantarjian H, O'Brien S,et al. Topotecan, a topoisomerase I inhibitor, is active in the treatment of myelodysplastic syndrome and chronic myelomonocytic leukemia[J].Blood,1996 ,88(7):2473-2479.
3Kraut EH, Balcerzak SP,Young D ,et al. A phase II study of topotecan in non-Hodgkin's lymphoma: an Ohio State University phase Ⅱ research consortium study[J].Cancer Invest,2002,20(2): 174-179.
4Kraut EH, Crowley JJ, Wade JL,et al. Evaluation of topotecan in resistant and relapsing multiple myeloma: a Southwest Oncology Group study[J].J Clin Oncol,1998,16(2):589-592.
5Estey EH. Comparison of idarubicin + ara-C-, fludarabine + ara-C-, and topotecan + ara-C-based regimens in treatment of newly diagnosed acute myeloid leukemia, refractory anemia with excess blasts in transformation, or refractory anemia with excess blasts[J].Blood, 2001 , 98(13): 3575-3583.
6Pagano L, Mele L,Voso MT,et al. The association of topotecan and cytarabine in the treatment of secondary or relapsed acute myeloid leukemia[J].Haematologica, 2001, 86(4): 440-441.

医学临床研究

2004年第2期

内容加载中请稍等...